Retension Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Key Highlights
- ➤IPO raised $51.75 million gross and approximately $45.1 million net proceeds
- ➤Phase 2b trial of RTN-001 targets approximately 280 uncontrolled-hypertension patients
- ➤Phase 2b topline data expected in the first half of 2027
- ➤Third-quarter net loss widened to $5.9 million from $1.5 million
- ➤Third-quarter R&D expense increased to $5.0 million from $1.4 million
Expert Statements
Eric Keller, Chief Executive Officer of Retension Pharmaceuticals
“Completing our initial public offering was an important step for Retension, and it provides the capital to complete our Phase 2b clinical trial of RTN-001 and prepare for Phase 3”
Eric Keller, Chief Executive Officer of Retension Pharmaceuticals
“This year we have also built a leadership team with deep experience advancing cardiovascular and metabolic therapies from clinical development through approval, and formed a Scientific Advisory Board of leading investigators in hypertension, cardiology and nephrology”
Eric Keller, Chief Executive Officer of Retension Pharmaceuticals
“We remain focused on executing the Phase 2b trial, with initial data expected in the first half of 2027, as we work to bring a new treatment option to patients with uncontrolled and resistant hypertension”
* IPO completed in October 2026 to support the continued development of RTN-001 for uncontrolled and resistant hypertension, affecting ~30 million Americans * Upsized IPO generated $51.75 million in gross proceeds * Topline data for Phase 2b clinical trial expected in first half of 2027 FALLS CHURCH, Va., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Retension Pharmaceuticals, Inc. (Nasdaq: RTSN) (“Retension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update.
“Completing our initial public offering was an important step for Retension, and it provides the capital to complete our Phase 2b clinical trial of RTN-001 and prepare for Phase 3,” said Eric Keller, Chief Executive Officer of Retension Pharmaceuticals. “This year we have also built a leadership team with deep experience advancing cardiovascular and metabolic therapies from clinical development through approval, and formed a Scientific Advisory Board of leading investigators in hypertension, cardiology and nephrology. We remain focused on executing the Phase 2b trial, with initial data expected in the first half of 2027, as we work to bring a new treatment option to patients with uncontrolled and resistant hypertension.”
Get started
Create a free account to read the full story.
